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ABSTRACT 
Objectives: a) To determine serum 25-OH vitamin D (vitD) levels in primary 
antiphospholipid syndrome (APS) and to compare them with patients with positive 
antiphospholipid serology who do not meet clinical criteria for APS, and with healthy 
controls. b) To analyze the association of vitD levels with both the clinical 
manifestations and the immunological profile of patients with primary APS. c) To 
perform a meta-analysis evaluating potential differences in serum vitD levels between 
APS and controls as well as the frequency of vit D deficiency in APS patients. 
Methods: Retrospective study including 74 patients with primary APS, 54 with positive 
antiphospholipid (aPL) serology not meeting clinical criteria for APS and 215 healthy 
controls. We considered 30 ng/ml and 10 ng/ml as the thresholds for vitamin D 
insufficiency and deficiency, respectively. Meta-analysis included 4 case-control studies 
(325 primary APS patients and 507 controls) and was conducted by fitting random 
effects models and checked for heterogeneity. 
Results: Median serum vitD levels were similar in the three groups:  21 ng/ml in 
primary APS, 25 ng/ml in the aPL-positive group, and 21 ng/ml in controls (p=0.115).  
However, we found differences in the PTH levels, being 40.4 ± 24.9 pg/ml in APS, 34.1 
± 18.2 pg/ml in aPL serology and 23.4 ±12.6 pg/ml in healthy controls (p<0.001). 
Regarding vitamin D deficiency, we found significant differences across the groups: 
16.2% in APS, 11.1% in patients with positive serology and 3.7% in controls (p=0.001). 
There was a trend for the presence of thrombotic events in patients with vitamin D 
deficiency (38.9% vs 19.1%, p=0.071). The meta-analysis confirmed that the combined 
mean difference in serum vitD levels between APS and controls was -3.605 (p <0.001) 
and that APS patients had an increased frequency of vitD deficiency, with an OR 3.06 
(95% CI 2.12 - 4.43, p<0.001).  
Conclusions: APS patients show higher frequency of vitD deficiency than the healthy 
individuals. The meta-analysis study, including three cohorts and ours, suggests that 
APS patients have significantly lower serum vitD levels and higher frequency of vitD 
deficiency than controls. 
 




Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the 
presence of antiphospholipid antibodies (aPL) and at least a clinical event defined as 
thrombosis and/or pregnancy morbidity [1] APS may also appear associated with an 
underlying systemic autoimmune rheumatic disease. The prevalence of aPL in the 
general population is around 5% [2]. Transiently positive serology may appear in some 
infections and in any inflammatory state [2;3]. In patients with systemic lupus 
erythematosus (SLE), aPL are present in up to 41% even in the absence of APS [4].
 
Vitamin D (VitD) has a very well known role in bone metabolism and calcium 
homeostasis, having also important immunomodulatory functions [5]. Its deficiency has 
been linked to the pathogenesis and clinical manifestations of autoimmune diseases 
such as diabetes, multiple sclerosis, Crohn disease, rheumatoid arthritis, SLE or Sjögren 
syndrome [6-9]. 
 
Moreover, in vitro models have shown that vitD inhibits the expression of tissue factor 
(TF) in monocytes stimulated by anti-beta 2 glycoprotein I (aB2GPI) antibodies derived 
from APS, suggesting a potential role of vitD in the pathogenesis of the disease [10]. 
Some case-control studies have reported low serum levels of vitD in APS patients as 
well as high frequency of vitD deficiency [10-14]. However, some of those studies lack 
of a control population, include small samples and none of them evaluate patients with 
isolated aPL serology without fulfilling the clinical criteria for APS. 
The aims of the present study were a) to determine serum vitD levels in patients with 
primary APS and to compare them with patients with positive aPL who do not meet 
clinical criteria for APS, and with healthy controls, b) to analyze the association of the 
vitD levels with both the clinical manifestations and the immunological profile of 
patients with primary APS and c) to perform a metaanalysis evaluating potential 
differences in serum vitD levels between APS and controls as well as the frequency of 
vitD deficiency in APS patients. 
 
2. MATERIAL AND METHODS 
2.1 Study population 
We conducted a retrospective study including patients attending the Rheumatology 
clinic from a tertiary center in Northern Spain  from January 2007 to December 2013. 
We included 74 patients with primary APS (all of  them met Sidney classification 
criteria [1]), 54 with positive aPL serology not meeting clinical criteria for APS and 215 
healthy controls consisting of voluntary adults from the general population attending a 
primary care center. They were frequency matched for age and sex. None of the patients 
met the ACR classification criteria for SLE or other concomitant autoimmune disease. 
In order to evaluate seasonal variations of serum vitD levels, patients and controls were 
grouped according to two time points: sunny season (July to October) and dark season 
(November to June).  
 
2.2 Laboratory tests 
IgG and IgM anticardiolipin (aCL) and aB2GPI levels were measured measured in real 
time in our routine by ELISA (Aesku diagnostics, Wensdelsheim, Germany) and 
expressed in GPL or MPL units or U/ml, respectively.  Titers were considered to be 
positive when they were above the 99
th
 percentile, thus corresponding to 20 GPL, MPL 
or U/ml.  We considered positive those titers reported as medium (20-30) or high (>30), 
being low titers considered as negative.  
Lupus anticoagulant was determined according to the standard guidelines Subcomitee 
on Lupus Anticoagulant/antiphospholipid antibody (scientific and standardization 
Committee of the International Society of Thrombosis and Haemostasis)[15]. 
 
Samples from routine aPL tests were frozen at -80ºC and used to measure in a single run 
25-OH vitamin D and intact PTH. Serum 25-OH vitamin D concentration was measured 
by automated competitive chemiluminiscence assay (Liaison XL, DiaSorin Inc, 
Stillwater MN USA). Our laboratory is DEQAS (Vitamin D External Quality 
Assessment Scheme). Minimum detectable concentration was estimated to be 4 ng/ml. 
We considered 30 ng/ml and 10 ng/ml as the thresholds for vitamin D insufficiency and 
deficiency, respectively [16;17]. Total intact PTH was measured by specific automated 
chemiluminiscence assay (iSYS, IDS-iSYS Multi-Discipline Automated Analyser, 
Pouilly-en Auxois, France). The sensitivity of the PTH assay was 5 pg/ml. Normal 
values were considered as below 45 pg/ml.  
 
2.3 The meta-analysis 
A comprehensive search of PubMed and Cochrane database was completed and 
supplemented by hand searching of the references of all selected articles. “Vitamin D 
and antiphospholipid syndrome” without restriction to any language published up to 
March 2017.This meta-analysis followed the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines [18]. 
 
Studies that included patients with APS and vitD were reviewed as shown in the flow 
chart. Figure 1. Information was collected on study design, study sample, 
characteristics of the study population, serum vitD levels and vitD deficiency definition.  
 
2.4 Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics for Windows version 
15 (Armonk, NY: IBM Corp.). Median and ranges or mean values and standard 
deviations were calculated for the continuous variables. Between-group differences 
were analyzed using the Student t-test, ANOVA or the chi square tests. A 2-tailed p< 
0.05 was considered statistically significant.  
Meta-analyses were conducted by fitting random effects models and were checked for 
publication bias by funnel plots as shown in supplementary Figure 1 [19]. I
2
 statistic was 
calculated to quantify the proportion of the total variation owing the heterogeneity [20] 
Statistics were performed using Comprehensive Meta-analysis, version 2.0 
(Biostat,Englewood, NJ, USA) [21]. 
 
3. RESULTS  
The main clinical and laboratory features of the study population are summarized in  the 
table 1. 
 
Table 1. Main clinical and immunological features of the study population 






Age, yrs (mean ± SD) 46.1  ± 15.3 49.2  ± 17.2 49.8±8.9 0.08 
Women, n (%) 65 (90.3) 42 (84) 175 (81.4) 0.210 
Smoking, n (%) 30 (40.5) 16 (30.2) ND 0.27 
Hypertension, n (%) 24 (32.4) 13 (24.5) ND 0.43 
Dyslipidemia, n (%) 22 (29.7) 8 (15.1) ND 0.06 
Diabetes, n (%) 6 (8.1)  2 (3.8) ND 0.47 
Clinical 




















57 (77) 48(90.6) NA 0.06 
Positive aB2GPI 
antibodies, n (%) 
49 (66.2) 37 (69.8) NA 0.71 
Positive lupus 
anticoagulant, n (%) 
23 (54.8) 15 (44.1) NA 0.49 
Number of positive 









































Abbreviations: APS: antiphospholipid syndrome, aPL: antiphospholipid, aCL: anti-
cardiolipin, aBGPI:anti-beta 2 glycoprotein I, NA: non-applicable, SD: standard 
deviation, IR: interquartile range. 
 
Overall, 20.5% of measurements were performed during the sunny season. As expected, 
higher levels of vitD were found in this period (median 25 ng/ml; range 10-69 vs 20 
ng/ml; range 4-105, p <0.001). Seasonal variation was observed in both APS and 
controls, but no statistically significant differences were observed in the aPL serology 
group.  
 
Median levels of vitD were similar in the three groups:  21 ng/ml (range 5-69) in 
primary APS, 25 ng/ml (4-50) in the aPL-positive group, and 21 ng/ml (7-105) in 
healthy controls (p=0.115).  However, we found differences concerning serum PTH 
levels, being 40.4 ± 24.9 pg/ml in APS, 34.1 ± 18.2 pg/ml in aPL serology and 23.4 
±12.6 pg/ml in controls (p<0.001). Post hoc analysis confirmed the differences in PTH 
levels between both APS and aPL with controls. 
As shown in Figure 2, we found no significant differences in the frequency of vitD 
insufficiency among the three groups (p=0.222). However, there were differences in the 
prevalence of vitD deficiency across the groups (p=0.001) 
 
APS patients were classified as thrombotic and obstetric phenotype. We found no 
differences in serum vitD levels according to these clinical phenotype (median 19 
ng/ml; range 6-44 in thrombotic APS vs 22 ng/ml; range 6-69 in obstetric APS; 
p=0.292), neither globally nor stratifying by season. There was no significant 
association between vitD insufficiency and the presence of thrombotic or obstetric 
events. Nevertheless, we found a trend for the presence of more thrombotic events in 
patients with vitamin D deficiency (38.9% vs 19.1%; p=0.071). 
 
Regarding the autoantibodies profile, we found no association between vitD 
insufficiency and the number of positive antibodies, or the presence of either aCL or 
aB2GPI antibodies. However, we found an association between vitD insufficiency and 
the presence of lupus anticoagulant (54.7 % vs 18.2%, p=0.047). When the analysis was 
restricted to APS patients, we found an association between vitD insuffiency and higher 
number of positive antibodies and positivity for aB2GPI (p=0.050 and p =0.023, 
respectively). No association was found between vitD deficiency and the 
immunological profile. 
 
In line with traditional cardiovascular risk factors and serum vitD levels, we found a 
trend between dislypidemia and vitD insufficiency (27.8% vs 10.3%, p=0.080)  that 
persisted when we restricted the analysis to the aPL serology group (21.6% vs 0%, 
p=0.088). There was also a trend for an association between insufficient vit D levels and 
hypertension (32.4 % vs 6.3%, p=0.079) in the aPL serology group. We also studied the 
association between traditional cardiovascular risk factors and vitD deficiency, with a 
tendency of association with diabetes mellitus (16.7% vs 4.6%, p=0.085), and with 
tobacco use when we restricted the analysis to the APS group (66.7% vs 
35.5% ,p=0.058). 
 
Vitamin D levels are decreased in patients with APS 
 
Only three studies had previously provided data on serum vitD levels in APS patients 
and controls. As detailed in Table 2, Agmon-Levin [10] et al., included both patients 
with primary and secondary APS, while the rest of authors included only primary APS 
patients.  
The meta-analysis (Figure 3a) showed that the combined mean difference in vitD levels 
between APS and controls was -3.605 (SE 0.941, p <0.001). No heterogeneity was 
detected in the studies analyzing mean serum vitD levels, I
2




Vitamin D deficiency is more frequent in APS patients than in controls 
Four studies provided data on the frequency of vitD deficiency in APS patients.  As 
shown in the table 2, the threshold for vitD deficiency was not homogeneous. This was 
taking into account, as explained in the statistical analysis section. The metaanalysis of 
these four studies showed that APS patients have an increased frequency of vitD 
deficiency, with an OR 3.06 (95% CI 2.12 - 4.43, p<0.001) (Figure 3b). There is some 
evidence suggestive of mild heterogeneity between the four studies; I
2
 24.7%(95%CI: 
0.0 - 90.3%). 
 
Table 2. Main demographic and clinical characteristics of the patients reported in 
previous literature 
 
























Population ND Brazil Brazil European Italian Spanish 
Number of 
patients 






Control group No No 23 141 128 215 
Female 
sex, % 
ND 93.5 100 80 83 90 
Age, years, 
(mean ± SD) 
ND 40.2 ± 
11.9  
 33 ± 8.2  ND 46 [18-
79] * 
46.1  ± 
15.3 
White race % ND 82.6 86.9 ND 96 ND 
25 OH vitD, 













- 30  - 30  30  30  
Insufficient 
levels, % 
ND 74% ND 51.4% 77% 82% 
Deficiency 
threshold 
20 10 20 15 10 10 
Deficient 
levels, % 
ND 11%  56.5%  49.5% 17%  16.2% 
Venous 
thrombosis, % 
ND 63 82.6%  ND 41  
50% 




ND 28.3 43.5 ND 36 54 
 
Abbreviations: ND no data, # studies not included in the meta-analysis due to a lack of 
control group, * median [range] 
 
 
4. DISCUSSION  
It has been suggested that vitamin D may play a role in the pathogenesis of APS [8;11]. 
Furthermore, a few studies have found a higher frequency of vitamin D deficiency in 
APS [10;13;14].  In the present study, we included 74 patients with primary APS, 54 
with a positive aPL serology and 215 healthy controls. There were no differences in 
serum vitD levels among the groups, but APS patients had higher frequency of vitD 
deficiency than aPL and controls. Moreover, we found a trend towards an association 
between vitD deficiency and the presence of thrombotic events.  The meta-analysis 
confirmed that APS patients have lower levels of vitD and higher frequency of vitD 
deficiency than the control population. 
 
Previous studies have reported lower serum vitD levels and higher frequency of vitD 
insufficiency in APS patients. However, in initial studies a control group was lacking 
(Table 2)[11;13]. Further studies, included a control population and confirmed that APS 
patients show a higher frequency of vitD insufficiency and/ or deficiency[10;13;14]. 
Regarding vitD serum levels, some authors found lower levels in APS patients [10;13] 
while others found differences only during the summer period but not in spring [14]. 
We did not find significant differences when comparing median serum vitD levels 
among the three groups. However, intact PTH levels were significantly higher in APS 
group, suggesting a reactive increase in response to lower levels of vitD [22-24].  
Most of previous studies included only patients with primary APS. Nevertheless, 
Agmon et al. [10] also included patients with secondary APS. They showed that those 
with secondary APS had lower vitD levels than patients with primary APS, and both of 
them lower than controls. This fact could be explained by the sun avoidance and the use 
of sunscreens in patients with SLE the presence of renal disease, or the use of some 
medications such as steroids. Overall, the finding of low vitD levels in APS patients 
keeps in line with the suggested role of vitD in the pathogenesis of many autoimmune 
conditions such as rheumatoid arthritis, diabetes or multiple sclerosis [8]. In fact, it is 
well known that vitamin D has regulatory properties in the immune system. Thus, it 
regulates the differentiation and activation of CD4+ lymphocytes, inhibits the 
differentiation of dendritic cells, as well as the differentiation from monocytes to 
macrophages, preventing them from releasing inflammatory cytokines and chemokines 
[11]. Besides, vitD deficiency is associated with impaired TLR function in aged 
subjects [5]. Moreover, it reduces IL-12 production and so, IL12-mediated Th1 
responses and the production of IFN-gamma and IL-2 [25]. On the other hand, it 
increases IL-10 and promotes Th2 type T helper function.  Regarding B cells, vitD has 
shown to inhibit antibody secretion and autoantibody production [26]. 
Regarding traditional cardiovascular risk factors, we found some trend, albeit non-
significant, for an association between vitD insufficiency and both dyslipidemia and 
hypertension. Moreover, there was a trend towards an association between vitD 
deficiency, diabetes and tobacco use in APS and aPL patients. Additionally, there was a 
trend, although not statistically significant, for differences in the frequency of 
dyslipidemia between APS and aPL, and the overall frequency of patients with 
cardiovascular risk factors was low. Therefore, other studies in larger populations are 
needed in order to elucidate the interactions between vitD availability, traditional 
cardiovascular risk factors and cardiovascular outcomes. There is poor evidence about 
the association between traditional cardiovascular risk factors and vitD deficiency in 
APS patients. Paupitz et al [13] found that vitD was inversely correlated with fat mass 
and fat percentage, confirming the findings by Klack [12] et al., and previous studies 
that demonstrated low vitD levels in obese individuals. This fact is in line with the 
previous knowledge, that in general population, low vitD status is associated with 
insuline resistance, hypertension, hyperlipidemia and diabetes and even with 
cardiovascular events [27;28]. Besides, in SLE patients low vitD has been associated 
with hypertension, hyperlipidemia [29] and diabetes [30]. The proposed pathogenic 
mechanisms include the dysregulation of calcium and phosphate homeostasis in cells 
and interstitial space, and serum PTH increase secondary to vitD deficiency that is 
considered a risk factor for cardiovascular disease and a predictor of cardiovascular 
events (probably due to a calcium overloading of cardiomyocytes). However, even 
though most of the vitD receptor knockout animal models support a causative role 
between vitD and vascular health, data from randomized studies does not uniformly 
support the assumption of a causal relationship, suggesting the possibility that low 
serum vitamin D levels in cardiovascular disease is only an epiphenomenon or merely a 
general marker of poor health [28].  Further studies are needed to elucidate this 
hypothesis.  
 
When analyzing APS clinical manifestations, we found that patients with vitD 
deficiency tended to have more thrombotic events than non-deficient ones. This finding 
keeps in line with previous studies that suggested an association between vitD and 
thrombosis in cancer patients [31] and general population [32;33]. Moreover, Andreoli 
et al [14] found that APS women with thrombotic manifestations had lower levels of 
vitD than women with pure obstetric disease during the summer period. Agmon et al., 
[10] also found an association between lower serum vitD levels and thrombotic events, 
as well as an association with pulmonary and ophthalmologic manifestations, livedo 
reticularis and skin ulcerations. This could be explained by the fact that aPL induced 
activation of endothelial cells and monocytes results in overexpression of tissue factor 
and adhesion molecules that are considered thrombogenic mechanisms in APS [34]. 
Agmon et al., [10] showed that vitD inhibited in vitro the expression of tissue factor 
induced by aB2GPI antibodies, therefore exerting an anti-thrombotic effect. However in 
our study vit D was measured at a time that was not necessarily the time of thrombosis, 
thus, many other factors can interfere the results. The association of vitamin D and 
thrombosis should be assessed in well-designed studies and also at the time of the 
thrombotic event. 
 
On the other hand, we did not find any association between vitD deficiency and 
obstetric outcomes. However, vitD deficiency has been linked with adverse pregnancy 
outcomes in general population [35-37]. Some of the pathogenic mechanisms suggest 
that vitD deficiency predisposes to a proinflammatory response, increases oxidative 
stress and leads to endothelial dysfunction. Moreover, vitD is thought to regulate genes 
responsible for trophoblast invasion and angiogenesis. There is very scarce information 
about the role of vitD and obstetric events in APS. Gysler et al., [38] suggested a 
combined treatment of low molecular weight heparin (LMWH) and vitD in pregnant 
women with APS, as they show that active vitD regulated aPL mediated inflammation 
and mitigate the release of antiangiogenic factors induced by LMWH. 
 
 
We found an association between vitD insufficiency and lupus anticoagulant. When we 
restricted the analysis to APS patients, we found an association between aB2GPI and a 
higher number of positive antibodies and vitD insufficiency. This finding keeps in line 
with in vitro studies showing that active vitD reduced antibody secretion and 
autoantibody production in SLE patients [26]. Regarding APS patients, only Paupitz et 
al., [13] evaluated the autoantibodies profile and the vitD status. They found no 
correlation between serum 25OHD levels and aCL. A recent preliminary study [39] 
reported that in APS patients, vitamin D supplementation might be associated with 
decreased serum aB2GPI levels. 
 
Our study has some limitations due to its retrospective design. Firstly, obesity that has 
been proposed to influence vitD levels in APS patients [12] was not recorded.  Secondly, 
data on cardiovascular risk factors were missing in the control population. Thirdly, we 
could not analyze the effect of treatments, as they were considered as ever treatment, 
with no data about if they were prior or posterior to the determination of vitD serum 
levels. Finally, few studies were included in the metaanalysis and the thresholds for 
vitD insufficiency and/or deficiency were not homogeneous.  
However, the high number of patients included in the study, the homogeneity of our 
population, the sex and age comparable control group, as well as the immunological 
profile and the statistical adjustments performed in the meta-analysis support our results. 
 
In summary, our study suggests that APS patients have significantly lower serum 
vitamin D levels and higher frequency of vitamin D deficiency than healthy controls.  
Further studies are needed to assess the association between vitD and thrombosis in 
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Figure 1. Flow diagram of the study selection process. 
 
 
Figure 2. Frequencies of vitamin D insufficiency and deficiency in APS, patients with 
positive serology and controls. * p=0.001  
 
Figure 3. Forest plot showing a) Differences in serum vitD levels between APS and 
controls.  b) Differences in the frequency of vitD deficiency between APS and controls.  
 
 
 
 
 
